Quince Therapeutics, Inc. announced a strategic relationship with Option Care Health, Inc., the nation's largest independent provider of home and ambulatory infusion services. This partnership aims to support the commercial development and efficient launch of Quince's lead asset, eDSP, in the U.S.
Option Care Health will serve as the specialty infusion therapy provider for the administration of eDSP, which is being developed for the treatment of Ataxia-Telangiectasia (A-T). This collaboration is a critical step in preparing for the potential commercialization of eDSP.
The partnership leverages Option Care Health's extensive network and expertise in infusion services, which is essential for a drug-device combination product like eDSP that requires specialized administration. This move helps to solidify Quince's commercial development planning ahead of potential regulatory approvals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.